Als | search
Click here to view Als news from 60+ newspapers.
Bookmark or Share
Amyotrophic lateral sclerosis (a-my-o-TROE-fik LAT-ur-ul skluh-ROE-sis), known as ALS, is a nervous system disease that affects nerve cells in the brain and spinal cord. ALS causes loss of muscle control. More @Wikipedia
Get the latest news about Als from the top news sites, aggregators and blogs. Also included are videos, photos, and websites related to Als.
Hover over any link to get a description of the article. Please note that search keywords are sometimes hidden within the full article and don't appear in the description or title.
- Amyotrophic lateral sclerosis (ALS) - Symptoms and causesAmyotrophic lateral sclerosis (a-my-o-TROE-fik LAT-ur-ul skluh-ROE-sis), known as ALS, is a nervous system disease that affects nerve cells in the brain and spinal cord. ALS causes loss of muscle control.
- Most Cases of ALS Do Not Run in Families - Mayo Clinic News NetworkMost cases of amyotrophic lateral sclerosis (ALS) are not familial and do not run in families. In a minority of ALS cases, though, the disease may be inherited and occur in multiple family members. Not all gene mutations responsible for the inherited form of ALS have been identified.
- Housecall: Understanding ALS - Mayo Clinic News NetworkLou Gehrig's disease, also known as amyotrophic lateral sclerosis or ALS, is a progressive nervous system disease that destroys nerve cells and causes disability. ALS often begins with muscle twitching and weakness in a limb, or slurred speech.
- Learn more about amyotrophic lateral sclerosis, or ALSAmyotrophic lateral sclerosis (a-my-o-TROE-fik LAT-ur-ul skluh-ROE-sis), or ALS, is a progressive nervous system (neurological) disease that destroys nerve cells and causes disability. ALS is often called Lou Gehrig's disease, after the famous baseball player who was diagnosed with it.
- Mayo Clinic awarded federal grant to study experimental ALS drugMayo Clinic in Florida has received a grant to begin an innovative study that will provide hundreds of patients with amyotrophic lateral sclerosis (ALS) access to an experimental drug over six months.
More
